Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.

Autor: Skryabin VY; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia., Zastrozhin MS; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia., Grishina EA; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia., Ryzhikova KA; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia., Shipitsyn VV; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia., V Barna I; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia., Galaktionova TE; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia., Ivanov AV; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia., Sorokin AS; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia., Bryun EA; Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia., Sychev DA; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow, Russia.

Publikováno v: Journal of pharmacy practice [J Pharm Pract] 2022 Aug; Vol. 35 (4), pp. 518-523. Date of Electronic Publication: 2021 Feb 24.

Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.

Autor: Zastrozhin MS; Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russia.; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Sorokin AS; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Agibalova TV; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Grishina EA; Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russia., Antonenko AР; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Rozochkin IN; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Duzhev DV; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Skryabin VY; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Galaktionova TE; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Barna IV; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Orlova AV; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Aguzarov AD; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Savchenko LM; Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russia., Bryun EA; Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russia.; Moscow Research and Practical Centre on Addictions, Moscow Department of Healthcare, Moscow, Russia., Sychev DA; Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russian Federation, Moscow, Russia.

Publikováno v: Human psychopharmacology [Hum Psychopharmacol] 2018 Nov; Vol. 33 (6), pp. e2677. Date of Electronic Publication: 2018 Oct 25.

Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.

Autor: M. S., Zastrozhin, VYu, Skryabin, VYu, Smirnov, A. K., Zastrozhina, E. V., Kaverina, D. A., Klepikov, E. A., Grishina, K. A., Ryzhikova, I. V., Bure, E. A., Bryun, D. A., Sychev

Publikováno v: Psychopharmacology Bulletin; 2021, Vol. 51 Issue 2, p31-42, 12p

The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6∗4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder.

Autor: Zastrozhin, Smirnov, Petukhov, Pankratenko, Zastrozhina, Grishina, Ryzhikova, Bure, Skryabin, Vlasovskih, Bryun, Sychev

Publikováno v: Psychopharmacology Bulletin; 2020, Vol. 50 Issue 3, p58-75, 18p